In summary, this study provides solid evidence that a more sensitive and specific therapeutic approach for NB may be achieved by blocking the ALK signaling pathway simultaneously through the directed ALK gene knockdown by ALK-siRNA nanoliposomal formulation in combination with the pharmacological inhibition of the ALK kinase activity by X-396. The gene discussed is ALK; the disease is neuroblastoma.